Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Rectal Neoplasms 1Neoplasms 1Lung Neoplasms 1Intestinal Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Ductal 1Breast Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma 1

Interventions

Psychiatric Rehabilitation 8Magnetic Resonance Spectroscopy 7Gemcitabine 7Capecitabine 7pembrolizumab 6Early Intervention, Educational 6Drug Therapy 6Cyclophosphamide 6Methods 5Therapeutics 4Specimen Handling 4Mental Status and Dementia Tests 4Docetaxel 4veliparib 3selpercatinib 3sargramostim 3palbociclib 3cediranib 3Trastuzumab 3Surveys and Questionnaires 3Standard of Care 3Radiotherapy 3Paclitaxel 3Oxaliplatin 3Irinotecan 3Fluorodeoxyglucose F18 3Counseling 3Cisplatin 3Carboplatin 3Bortezomib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Colonic Neoplasms × nazartinib × Breast × Clear all
NCT02900664 2022-03-29

A Study of PDR001 in Combination With CJM112, EGF816, IlarisĀ® (Canakinumab) or MekinistĀ® (Trametinib)

Novartis

Phase 1 Completed
283 enrolled
BreastGastrointestinalThoracic

Adenocarcinoma of Lung, Adenocarcinoma, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Intestinal Neoplasms, Lung Neoplasms, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms, Carcinoma, Ductal, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚔